Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by fuzzyjron Jun 08, 2018 11:41am

188 Views

Post# 28146093

I agree with Led...

on his assement of the answer Bear recieved back from Sarah,

one of Bears questions:

"Will the resuts of the SSRA be announced or will Resverlogix keep them confidential?"

Sarahs response:

"Yes it "would" be press released."

wtf?

Why not use the word "will" instead of "would" is my question?
- it would be released but sh it happens ...
- it would be released but we have a deal pending on the SSRA so we may not have to release it & on & on & on.
YES,IT WILL BE RELEASED - no confusion but thats not RVX communication style & quite posibly thats the only way she could answer it - who knows? Someone does.
Glta

Bullboard Posts

Why invest?